Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fully-Human Anti-CD19 CAR T Cells for B-cell Malignancies
NCT02659943Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jun 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of mivocabtagene autoleucel in B cell lymphoma and chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Primary endpoint: Percentage of Enrolled Participants Who Actually Get Treated. Started Jan 2016; status: completed.
02
Drugs
mivocabtagene autoleucel
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02659943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659943.